Marcela D Salazar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marcela D Salazar has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Iman Md Mohamed
Ruppert Health Center
1 shared publication - Ivana Kisovic
Department of Biochemistry and Cancer Biology, Medical University of Ohio, 3000 Arlington Avenue, Toledo, OH 43614, USA
1 shared publication - Manohar Ratnam
University of Toledo College of Medicine
1 shared publication - Maya Ratnam
Department of Biochemistry and Cancer Biology, Medical University of Ohio, 3000 Arlington Avenue, Toledo, OH 43614, USA
1 shared publication - Mugdha Patki
Department of Biochemistry and Cancer Biology, Medical University of Ohio, 3000 Arlington Avenue, Toledo, OH 43614, USA
1 shared publication - Robert J. Trumbly
Department of Biochemistry and Cancer Biology, University of Toledo, College of Medicine, Health Science Campus, Toledo, OH, USA
1 shared publication
Latest Publications
- Open Access
- 7 February 2011
- Published by Springer Nature in Breast Cancer Research
- Vol. 13 (1) , R18
During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein
Current hormonal adjuvant therapies for breast cancer including tamoxifen treatment and estrogen depletion are overall tumoristatic and are severely limited by the frequent recurrence of the tumors. Regardless of the resistance mechanism, development and progression of the resistant tumors requires the persistence of a basal level of cycling cells during the treatment for which the underlying causes are unclear.
- 7 February 2011
- Published by Springer Nature in Breast Cancer Research
- Vol. 13 (1) , R18
Open AccessDuring hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein
Current hormonal adjuvant therapies for breast cancer including tamoxifen treatment and estrogen depletion are overall tumoristatic and are severely limited by the frequent recurrence of the tumors. Regardless of the resistance mechanism, development and progression of the resistant tumors requires the persistence of a basal level of cycling cells during the treatment for which the underlying causes are unclear.